Norris MD - Search Results

1

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.

Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD; Australian and New Zealand Children's Oncology Group. Sutton R, et al. Among authors: norris md. Br J Haematol. 2009 Aug;146(3):292-9. doi: 10.1111/j.1365-2141.2009.07744.x. Epub 2009 Jun 3. Br J Haematol. 2009. PMID: 19500099 Free article. Clinical Trial.

2

Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T-cell leukemia xenograft, LALW-2.

Norris MD, Haber M, Kavallaris M, Brian MJ, Lutze LH, White L, Stewart BW. Norris MD, et al. Cancer. 1991 Sep 1;68(5):981-7. doi: 10.1002/1097-0142(19910901)68:5<981::aid-cncr2820680512>3.0.co;2-w. Cancer. 1991. PMID: 1913492

3

Phenotypic and cytogenetic analysis of atypical multidrug resistance in human leukaemic cells selected with methotrexate at high concentration.

Kavallaris M, Haber M, Norris MD, Pittman SM, Reed C, Stewart BW. Kavallaris M, et al. Among authors: norris md. Cancer Lett. 1990 Jun 15;51(3):193-201. doi: 10.1016/0304-3835(90)90102-4. Cancer Lett. 1990. PMID: 1972035

4

Heterotransplantation of human lymphoid neoplasms using a nude mouse intraocular xenograft model.

White L, Trickett A, Norris MD, Tobias V, Sosula L, Marshall GM, Stewart BW. White L, et al. Among authors: norris md. Cancer Res. 1990 May 15;50(10):3078-86. Cancer Res. 1990. PMID: 2159371

5

Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein.

Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L, Stewart BW. Haber M, et al. Among authors: norris md. Cancer Res. 1989 Oct 1;49(19):5281-7. Cancer Res. 1989. PMID: 2569932

6

Atypical multidrug resistance in CCRF-CEM cells selected for high level methotrexate resistance: reactivity to monoclonal antibody C219 in the absence of P-glycoprotein expression.

Norris MD, Haber M, King M, Davey RA. Norris MD, et al. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1435-41. doi: 10.1016/0006-291x(89)92764-2. Biochem Biophys Res Commun. 1989. PMID: 2575383

7

Therapy-induced drug resistance in a human leukemia line (LALW-2). A clinically relevant model.

White L, Haber M, Brian MJ, Norris MD, Trickett A, Sosula L, Tiley C, Stewart BW. White L, et al. Among authors: norris md. Cancer. 1989 Jun 1;63(11):2103-10. doi: 10.1002/1097-0142(19890601)63:11<2103::aid-cncr2820631106>3.0.co;2-n. Cancer. 1989. PMID: 2720561

8

Resistance to drugs associated with the multidrug resistance phenotype following selection with high-concentration methotrexate.

Haber M, Reed C, Kavallaris M, Norris MD, Stewart BW. Haber M, et al. Among authors: norris md. J Natl Cancer Inst. 1989 Aug 16;81(16):1250-4. doi: 10.1093/jnci/81.16.1250. J Natl Cancer Inst. 1989. PMID: 2754745

9

Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJH primers.

Norris MD, Kwan E, Haber M, Marshall GM. Norris MD, et al. Leukemia. 1995 Oct;9(10):1779-82. Leukemia. 1995. PMID: 7564525

10

An assay for the determination of reduced methotrexate accumulation in cells displaying limited viability in vitro.

Haber M, Norris MD, Kavallaris M, Camacho M, Madafiglio J, Baker CJ, White L, Stewart BW. Haber M, et al. Among authors: norris md. Cancer Lett. 1995 Oct 20;97(1):49-55. doi: 10.1016/0304-3835(95)03950-2. Cancer Lett. 1995. PMID: 7585477

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

247 results

Search Page